FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A

If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia APDUFA Target Action Date is March 31, 2023SAN RAFAEL, Calif., O...

Related Keywords

United States ,Hank Fuchs ,Debra Charlesworth ,Traci Mccarty ,European Commission ,Drug Administration ,Biomarin Pharmaceutical Inc ,Nasdaq ,Exchange Commission ,Worldwide Research ,Prnewswire Biomarin Pharmaceutical Inc ,Robust Clinical Program ,Gene Therapy ,Severe Hemophilia ,Action Date ,Marin Pharmaceutical ,Biologics License Application ,Prescription Drug User Fee Act ,Regenerative Medicine Advanced Therapy ,Breakthrough Therapy Designation ,Biomarin Pharmaceutical ,Quarterly Report ,